_보령 리큐비이엑스정.jpg)
Boryung Consumer Healthcare has released an over-the-counter version containing the nation’s highest-ever dosage of benfotiamine.
High-content active vitamin products have become best-seller OTCs at pharmacies, but they are now in a transitional period of “super vitamin” content.
Boryung Consumer Healthcare, the healthcare unit of Boryung Pharmaceutical Group, launched “Recuvi EX” tablets on the market Dec. 10, an active vitamin B product containing benfotiamine.
Recuvi EX tablet was introduced by NBK Pharma as the nation’s first active vitamin B OTC version of Bentiv.
Recuvi EX tablets each contain 300mg of benfotiamine and 100 mg of pyridoxine. Benfotiamine is designed to improve fatigue by preventing the accumulation of lactic acid in neurotransmitters.
It is believed to be efficacious in improving diabetic neuropathy and restoring alcoholic neural damage, improving recognition and brain functions.
Absorption of benfotiamine is faster than that of conventional vitamin B1 material, thiamine or fursultiamine, and its bioavailability is high, so the former has maintained fast growth in recent years.
Content of benfotiamine, effective in restoring fatigue, is on the rise with G4 meeting the needs of modern people.
Drugs with super content of benfotiamine are now available for medical treatment at drug stores. They are said to be particularly effective in preventing and improving complications of diabetes.
Research outcomes show that diabetes patients are susceptible to thiamine deficiency (vitamin B1) since they discharge it more than two times more than average people.
Diagnostic neuropathy patients, taking six weeks of 300mg or 600mg of benfotiamine, have seen neurologic symptom score improve: The more content, the more effective it is.
Users of Recuvi EX tablet find it easy to take the product since it is made to minimize the unique smell of vitamin B.
Pharmacists say that patients forget to take two doses daily, but they can take a pill of Recuvi EX per day.
An official with Recuvi EX said the material benfotiamine is called as a “treating vitamin,” so it has been widely used in the global OTC market in European countries such as Germany.
Clinical research outcomes of Recuvi EX, containing the nation’s largest-event active vitamin content, confirm efficacy in neuropathy diseases and improving recognition function, thus leading the high-content benfotiamine market.
